Trials / Completed
CompletedNCT00137748
Cytomegalovirus Hyperimmune Globulin (CMV-Ig) Replacement in Hypogammaglobulinemic Lung Transplant Recipients
Does Replacement With CMVIG in Hypogammaglobulinemic Patients Decrease the Rate of Opportunistic Infections and Chronic Rejection?
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- The Cleveland Clinic · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
Detailed description
This is a randomized controlled trial of CMV-Ig in lung transplant recipients at the Cleveland Clinic Foundation who are hypogammaglobulinemic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CMV-Ig | Drug: CMV-Ig |
Timeline
- Start date
- 2001-01-01
- Primary completion
- 2006-01-01
- Completion
- 2006-01-01
- First posted
- 2005-08-30
- Last updated
- 2010-06-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00137748. Inclusion in this directory is not an endorsement.